Cadence is a bank holding company. The company is engaged in commercial lending to middle-market customers and provide a range of commercial loans to middle-market commercial businesses, individuals and business owners. The company's loan portfolio includes commercial and industrial loans, residential real estate loans, commercial real estate loans and other consumer loans. The company also provides its customers a variety of deposit products, including checking accounts, savings accounts, money market accounts and other deposit accounts, through multiple channels, including its network of full-service branches, drive-thru branches, ATMs, ITMs, and its online, mobile and telephone banking platforms.

Golub Capital BDC is registered as an externally managed, closed-end, non-diversified management investment company. The company makes investments primarily in one stop (a loan that combines characteristics of first lien senior secured loans and second lien or subordinated loans) and other senior secured loans of middle-market companies that are, in most cases, sponsored by private equity firms. The company's investment objective is to generate existing income and capital appreciation by investing primarily in one stop and other senior secured loans of United States middle-market companies.

Selecta Biosciences is a biopharmaceutical company using its ImmTOR? platform, designed to induce tolerance to biologic therapies that would otherwise be limited by immunogenicity to treat rare and serious diseases. The company's product candidate, SEL-212, is a combination of a therapeutic uricase enzyme (pegadricase) and its ImmTOR platform that is designed to control serum uric acid levels in patients with chronic refractory gout through monthly administration. The company is applying its ImmTOR platform to mitigate the formation of anti-drug antibodies when dosing gene therapy. The company's investigational gene therapy program targets the treatment of rare genetic diseases, including methylmalonic acidemia.

TRACON Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of targeted therapeutics for cancer and wet age-related macular degeneration. The company is developing its primary product candidate, TRC105 (carotuximab), an endoglin antibody, for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor pathway, or in combination with inhibitors of the programmed cell death protein 1 pathway. The company's second clinical stage product oncology candidate is TRC102, a small molecule being developed for the treatment of lung cancer and mesothelioma.